| Literature DB >> 28815411 |
Abeer M El-Naggar1, Mohsen M Abou-El-Regal2, Souad A El-Metwally3, Farag F Sherbiny4,5, Ibrahim H Eissa6.
Abstract
Thymidylate synthase (TS), one of folate-dependent enzymes, is a key and well-recognized target for anticancer agents. In this study, a series of 6-aryl-5-cyano thiouracil derivatives were designed and synthesized in accordance with essential pharmacophoric features of known TS inhibitors. Nineteen compounds were screened in vitro for their anti-proliferative activities toward HePG-2, MCF-7, HCT-116, and PC-3 cell lines. Compounds [Formula: see text], [Formula: see text], and 24 exhibited high anti-proliferative activity, comparable to that of 5-fluorouracil. Additionally, ten compounds with potent anti-proliferative activities were further evaluated for their ability to inhibit TS enzyme. Six compounds ([Formula: see text], [Formula: see text], [Formula: see text], 22, 23 and 24) demonstrated potent dose-related TS inhibition with [Formula: see text] values ranging from 1.57 to [Formula: see text]. The in vitro TS activity results were consistent with those of the cytotoxicity assay where the most potent anti-proliferative compounds of the series showed good TS inhibitory activity comparable to that of 5-fluorouracil. Furthermore, molecular docking studies were carried out to investigate the binding pattern of the designed compounds with the prospective target, TS (PDB-code: 1JU6).Entities:
Keywords: 6-Aryl-5-cyano thiouracil; Anticancer; Docking; Thymidylate synthase
Mesh:
Substances:
Year: 2017 PMID: 28815411 DOI: 10.1007/s11030-017-9776-1
Source DB: PubMed Journal: Mol Divers ISSN: 1381-1991 Impact factor: 2.943